Overcoming resistance to second-generation antiandrogens in prostate cancer

Robert Dreicer, MD, discusses emerging strategies for overcoming resistance to second-generation antiandrogens in prostate cancer. Second-generation antiandrogens approved by the FDA for the treatment of patients with prostate cancer include abiraterone acetate (Zytiga), enzalutamide (Xtandi), apalutamide (Erleada), and darolutamide (Nubeqa).

Dreicer is associate director for Clinical Research and deputy director of the University of Virginia Cancer Center; section head of Medical Oncology and co-director of the Paul Mellon Urologic Institute; and professor of Medicine and Urology at the University of Virginia School of Medicine.

Related Videos
Expert on prostate cancer
Expert on prostate cancer
Expert on prostate cancer
Dr. Jim C. Hu in an interview with Urology Times
Prostate cancer cell dividing | Image Credit: © PRB ARTS - stock.adobe.com
Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
© 2023 MJH Life Sciences

All rights reserved.